Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.77 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.77 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.77 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.77 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.66 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.66 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.66 |
| ▸ | POLB | P06746 | 1/20 | 0.65 |
| ▸ | HPGD | P15428 | 1/20 | 0.65 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.56 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28141546 | 0.94 | MAPT (0.69) | MAPTCYP1A2CYP2C9CYP2C19HDAC1 | |
| SCHEMBL11911355 | 0.91 | MAPT (0.65) | MAPTCYP1A2CYP2C9CYP2C19HDAC1 | |
| SCHEMBL14809773 | 0.87 | MAPT (0.60) | MAPTCYP1A2CYP2C9CYP2C19HDAC1 | |
| SCHEMBL17599519 | 0.87 | MAPT (0.60) | MAPTCYP1A2CYP2C9CYP2C19HDAC1 | |
| SCHEMBL14810361 | 0.87 | CYP1A2 (0.60) | MAPTCYP1A2CYP2C9CYP2C19HDAC1 | |
| SCHEMBL1548172 | 0.87 | MAPT (1.00) | MAPTCYP1A2CYP2C9CYP2C19HDAC1 | |
| SCHEMBL29960273 | 0.86 | MAPT (0.57) | MAPTCYP1A2CYP2C9CYP2C19HDAC1 | |
| SCHEMBL5789916 | 0.86 | MAPT (0.57) | MAPTCYP1A2CYP2C9CYP2C19HDAC1 | |
| SCHEMBL17599502 | 0.85 | CYP1A2 (0.58) | MAPTCYP1A2CYP2C9CYP2C19HDAC1 | |
| SCHEMBL5646672 | 0.84 | MAPT (0.56) | MAPTCYP1A2CYP2C9CYP2C19HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6956037-B2 | Benzamide derivatives for the treatment of diseases mediated by cytokines | ASTRAZENECA AB (SE) | 2005-10-18 | — | — | US | disclosed |
| EP-1077931-B1 | BENZAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY CYTOKINES | ASTRAZENECA AB (SE) | 2004-11-17 | — | — | EP | disclosed |
| US-20030212068-A1 | Benzamide derivatives for the treatment of diseases mediated by cytokines | ASTRAZENECA AB | 2003-11-13 | — | — | US | disclosed |
| US-6579872-B1 | Such as TNF, in particular of TNF alpha, and various interleukins, in particular IL-1; N-(5-(4-(3-hydroxypropoxy)benzamido)-2-methylphenyl)-3,4-dimethoxybenzamide | ASTRAZENECA AB (SE) | 2003-06-17 | — | — | US | disclosed |
| CN-1300278-A | Benzamide derivatives for the treatment of diseases caused by cytokines | ASTRA ZENECA LTD (SE) | 2001-06-20 | — | — | CN | disclosed |
| EP-1077931-A1 | BENZAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY CYTOKINES | AstraZeneca AB (SE) | 2001-02-28 | — | — | EP | disclosed |
| WO-1999059959-A1 | BENZAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY CYTOKINES | ASTRAZENECA AB (SE) | 1999-11-25 | — | — | WO | disclosed |
| US-4094636-A | DIAZOTIZATION | HOECHST AKTIENGESELLSCHAFT (DT) | 1978-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212068-A1 | Benzamide derivatives for the treatment of diseases mediated by cytokines | IL2, IL6, IL6ST | MAPT 4386/4885CYP1A2 151/4885CYP2C9 898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.